Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about the baseline and follow-up panel, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value. One out-of-range result in isolation generates anxiety and unnecessary tests; the same result next to the trend and the rest of the panel usually generates a shrug.
The condition it depends on
Reference ranges are laboratory-specific. Comparing your number to somebody else's range, or to a screenshot from another country, is how people convince themselves something is wrong.
The practical version
Post reference ranges alongside numbers when you share them. Units differ by country — glucose and lipids especially — and half the confusion in these threads is unit mismatch rather than disagreement.
What I am not sure about
So the question, as narrowly as I can put it: how often to repeat it, because quarterly seems to be the convention and I cannot find the reasoning. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
carl_compliance said:The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.
No disagreement with carl_compliance. One condition attached. Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c becomes informative again, since it reflects about three months of glycaemia. After the first year, and once doses are stable, annual is reasonable unless something specific is being followed.
Ask again with the specifics and you will get a better answer than this one.
carl_compliance said:The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.
This is where I part company with the consensus forming above. I would drop the "get everything" instinct further than this thread does. Every extra test is another chance at a false positive, and incidental findings have their own cost in scans, biopsies and worry.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemAnswering the narrow version, because the broad one does not have a single answer. A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin and B12, and a full blood count. That set catches the things that change, the things that explain symptoms, and the things that alter the prescribing decision. Almost everything else on the long circulating lists is either invariant, uninterpretable without a specific question, or an incidental finding waiting to cause an unnecessary workup.
Ask again with the specifics and you will get a better answer than this one.
Dr.AddMedPHL said:Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c…
Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.